GlobeNewswire Inc.··NaOrganon Scraps PCOS Drug Candidate, Dealing Second Blow to KDventures' Forendo Bet
Organon discontinues PCOS drug candidate, marking total failure of KDventures' 2021 Forendo acquisition. Contingent consideration fully written off after second portfolio termination.
OGNdrug development discontinuationForendo acquisition